41 – 50 of 157
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Abstract P2-10-07: Stem cell marker aldehyde dehydrogenase 1 in stromal cells strongly correlates with prognosis in breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Abstract P2-10-28: The Prognostic Index, KiGE, Combining Proliferation, Histological Grade and Estrogen Receptor Status Challenges Gene Profiling – A Study in 1,854 Chemo-Naïve Women with N0/N1 Primary Breast Cancer.
(
- Contribution to journal › Published meeting abstract
-
Mark
Abstract P2-10-19: Are the mitotic factors Mitotic Activity Index (MAI) and Phosphohistone 3 (PPH3) stronger prognostic proliferation factors than Ki67 in node-negative breast cancer?
(
- Contribution to journal › Published meeting abstract
-
Mark
A Prognostic Index Composed of Progesterone Receptor Status, Tumour Size and S-phase Fraction, Predicts Survival in Node-Negative Breast Cancer Patients in a Large Multicentre Prospective Cohort Study.
(
- Contribution to journal › Published meeting abstract
- 2013
-
Mark
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.
(
- Contribution to journal › Article
-
Mark
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
(
- Contribution to journal › Article
-
Mark
The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer.
(
- Contribution to journal › Article
-
Mark
The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
(
- Contribution to journal › Article
-
Mark
A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial.
(
- Contribution to journal › Article
-
Mark
Breast cancer survival in the US and Europe: a CONCORD high-resolution study
(
- Contribution to journal › Article